Harbin Pharmaceutical Group Co., Ltd. is a state-controlled Sino-foreign joint venture established in May 1989. There are two public companies listed on the Shanghai Stock Exchange (Harbin Pharmaceutical Group Co., Ltd. and Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.) and 27 wholly-owned, holding and shareholding companies. There are more than 20,000 employees with a registered capital of 3.7 billion yuan and total assets of11900 million yuan. After years of development, Harbin Pharmaceutical Group has formed the wings of the company's take-off with the continuous improvement of independent research and development system, growing scientific research team and strong brand. With this strong brand advantage, Harbin Pharmaceutical Group's independent research and development system has gained sufficient room for growth; The brand building of the company has also been strongly supported by the independent research and development system.

Harbin Pharmaceutical Group integrates pharmaceutical manufacturing, trade and scientific research, and its main business covers seven major industrial fields, including antibiotics, chemical pharmaceutical preparations, over-the-counter drugs and health food, traditional Chinese medicine, bioengineering drugs, animal vaccines and veterinary drugs, and pharmaceutical circulation. * * * It produces 7 series, more than 20 dosage forms and 1000 varieties of antibiotic raw materials and powder injections, Chinese patent medicines, powder injections and comprehensive preparations. All the production enterprises affiliated to Harbin Pharmaceutical Group have passed GMP certification, the main circulation enterprises have passed GSP certification, and some enterprises affiliated to Harbin Pharmaceutical General Factory and Sanjing Pharmaceutical Company have passed ISO900 1, ISO 1400 1, OHSAS 1800 1 international management system certification. Harbin Pharmaceutical Group has established more than 130 sales offices in more than 30 major urban areas in China, and has more than 200 retail chain pharmacies, forming a marketing network with wide coverage and strong functions.

Harbin Pharmaceutical Group adheres to the enterprise tenet of "being a genuine drug and being a kind enterprise", and its market share has rapidly increased and its business field has been continuously expanded. Some products have entered the markets of Europe, Asia, Africa, China and North America, earning more than $6,543.80 billion in foreign exchange through export. With the corporate philosophy of "combining reason, winning by surprise and surviving by virtue", we actively implemented the brand innovation strategy and won universal praise from all walks of life. Appraised by Beijing Brand Value Assets Appraisal Co., Ltd., an authoritative brand value appraisal institution in China, Harbin Pharmaceutical Group ranked 136. With a brand value of 8 1 100 million yuan, it has become one of the most valuable pharmaceutical brands in China.

Harbin Pharmaceutical Group currently owns four well-known trademarks of Harbin Pharmaceutical, Sanjing, Tang Shiyi and Calcium in Calcium in China, which are the highest in the whole industry and the three northeastern provinces.

Ambition determines the big pattern, and big vision determines the big future.

With the rapid expansion of Harbin Pharmaceutical Co., Ltd.' s business at home and abroad, Harbin Pharmaceutical Co., Ltd. sincerely invites talents at all levels at home and abroad to join us and seek common development of the pharmaceutical industry with its strong strength and broad development space. Harbin Pharmaceutical People are confident and capable of working with all partners to realize the promise of "delivering with heart and reaching the world smoothly".